Stockscreener 앱 받기
138.19
4.19%
-6.05
전일 마감가:
$144.24
열려 있는:
$144.78
하루 거래량:
300.20K
Relative Volume:
1.75
시가총액:
$5.54B
수익:
-
순이익/손실:
$-77.61M
주가수익비율:
-60.14
EPS:
-2.2979
순현금흐름:
-
1주 성능:
-2.28%
1개월 성능:
-3.36%
6개월 성능:
-7.34%
1년 성능:
+130.36%
1일 변동 폭
$136.09
$146.00
1주일 범위
$135.00
$146.00
52주 변동 폭
$56.10
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
138.19 | 5.78B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-26 | 개시 | BofA Securities | Buy |
| 2026-01-06 | 개시 | Morgan Stanley | Overweight |
| 2025-12-02 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-11-20 | 개시 | Mizuho | Neutral |
| 2023-12-14 | 개시 | Maxim Group | Buy |
| 2023-07-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 개시 | SVB Securities | Outperform |
| 2022-08-01 | 개시 | H.C. Wainwright | Buy |
| 2022-07-01 | 개시 | The Benchmark Company | Buy |
모두보기
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
BLTE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $200 - GuruFocus
The Technical Signals Behind (BLTE) That Institutions Follow - Stock Traders Daily
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 - markets.businessinsider.com
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 - GlobeNewswire Inc.
Belite Bio (NASDAQ: BLTE) completes FDA NDA submission for tinlarebant in Stargardt disease - Stock Titan
BLTE Stock Price, Quote & Chart - ChartMill
Belite Bio Shares Surge on Drug Filing Hopes - TipRanks
Precision Trading with Belite Bio Inc (BLTE) Risk Zones - Stock Traders Daily
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
Why Belite Bio Stock Is Sinking Again Today - TipRanks
Belite Bio Stock Tumbles as Wall Street Cools - TipRanks
Full Transcript: Belite Bio Q1 2026 Earnings Call - Sahm
Belite Bio Stock Slumps On Mounting Doubts - TipRanks
Belite Bio (BLTE) Hovers Near Resistance as Price Action Remains MutedBear Flag - The Legal Advocate
Mizuho lowers Belite Bio stock price target to $215 on valuation - Investing.com UK
Mizuho lowers Belite Bio stock price target to $215 on valuation By Investing.com - Investing.com South Africa
Mizuho Adjusts Price Target on Belite Bio to $215 From $223, Maintains Outperform Rating - Moomoo
Technical Reactions to BLTE Trends in Macro Strategies - Stock Traders Daily
Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE) - MSN
Benchmark reiterates Belite Bio stock rating on drug development progress By Investing.com - Investing.com Nigeria
Benchmark reiterates Belite Bio stock rating on drug development progress - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), Centene (CNC) - The Globe and Mail
Belite Bio: Buy Rating Reiterated as Tinlarebant Advances Toward 1Q27 Stargardt NDA Approval with Unchanged $200 Price Target - TipRanks
H.C. Wainwright reiterates Belite Bio stock rating on NDA progress By Investing.com - Investing.com South Africa
Earnings Scheduled For May 20, 2026 - Sahm
H.C. Wainwright reiterates Belite Bio stock rating on NDA progress - Investing.com
Belite Bio Q1 2026 Earnings Call Transcript - MarketBeat
Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses By GuruFocus - Investing.com Canada
Belite Bio Ramps Toward Tinlarebant Launch - TipRanks
Belite Bio Q1 Earnings Call Highlights - Yahoo Finance
Belite Bio (BLTE) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings call transcript: Belite Bio beats Q1 2026 EPS estimates, stock dips - Investing.com
Belite Bio Releases Q1 2026 Financial Results - AlphaStreet
Belite Bio Kicks Off Tinlarebant NDA and Ramps Up Commercial Build-Out on Strong Cash Base - TipRanks
Belite Bio Q1 Adjusted Loss Widens - marketscreener.com
Belite Bio stock gains 2% on first-quarter earnings beat By Investing.com - Investing.com India
Earnings Flash (BLTE) Belite Bio, Inc Posts Q1 Adjusted Loss $0.34 per Share, vs. FactSet Est of $-0.69 - marketscreener.com
Belite Bio stock gains 2% on first-quarter earnings beat - Investing.com
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update - The Manila Times
Belite Bio (NASDAQ: BLTE) starts tinlarebant NDA as Q1 2026 loss deepens - Stock Titan
Belite Bio receives Swiss orphan drug status for tinlarebant By Investing.com - Investing.com Nigeria
Belite Bio receives Swiss orphan drug status for tinlarebant - Investing.com
Belite Bio Inc Adr (BLTE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Belite Bio Inc Adr 주식 (BLTE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MATA NATHAN L. | Chief Scientific Officer |
May 06 '26 |
Sale |
153.84 |
1,000 |
153,839 |
666 |
| MATA NATHAN L. | Chief Scientific Officer |
May 05 '26 |
Sale |
155.50 |
1,000 |
155,502 |
1,666 |
| MATA NATHAN L. | Chief Scientific Officer |
May 04 '26 |
Sale |
155.64 |
1,000 |
155,636 |
2,666 |
| MATA NATHAN L. | Chief Scientific Officer |
May 01 '26 |
Sale |
155.78 |
1,000 |
155,778 |
3,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 30 '26 |
Sale |
156.97 |
1,000 |
156,973 |
4,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 29 '26 |
Sale |
155.82 |
1,000 |
155,817 |
5,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 28 '26 |
Sale |
159.16 |
1,000 |
159,162 |
6,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 27 '26 |
Sale |
162.64 |
1,000 |
162,641 |
7,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 24 '26 |
Sale |
159.56 |
1,000 |
159,556 |
8,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 23 '26 |
Sale |
166.28 |
1,000 |
166,284 |
9,666 |
1.27%
1.43%
자본화:
|
볼륨(24시간):